| AIM2 Protein |
|---|
| Protein Name | AIM2 (Absent in Melanoma 2) |
| Gene | [AIM2](https://www.ncbi.nlm.nih.gov/gene/9447) |
| UniProt ID | [Q9UBR9](https://www.uniprot.org/uniprot/Q9UBR9) |
| Molecular Weight | ~37 kDa |
| Subcellular Localization | Cytoplasm, nucleus |
| Protein Family | HIN-200 family (Pyrin/ AIM2-like receptors) |
| Ligand | Double-stranded DNA (dsDNA) |
AIM2 (Absent in Melanoma 2) is a critical cytosolic DNA sensor that plays a central role in the innate immune response by forming the AIM2 inflammasome. Discovered as a tumor suppressor whose loss contributes to melanoma progression, AIM2 has emerged as a key player in neuroinflammation and neurodegenerative diseases [1]. The AIM2 inflammasome detects foreign and endogenous double-stranded DNA in the cytosol, triggering a pro-inflammatory cascade that contributes to the chronic neuroinflammation observed in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions [2].
The AIM2 protein is expressed in various cell types within the central nervous system (CNS), including neurons, astrocytes, microglia, and oligodendrocytes. Its activation in these cell types contributes to the neuroinflammatory milieu that drives disease progression in multiple neurodegenerative disorders [3]. Understanding the AIM2 inflammasome pathway has become a major focus for developing therapeutic interventions aimed at modulating neuroinflammation in these devastating diseases.
AIM2 possesses a distinctive bipartite structure that enables its dual function as both a DNA sensor and an inflammasome scaffold:
¶ Pyrin Domain (PYD)
The N-terminal Pyrin Domain (approximately 90 amino acids) belongs to the death domain fold family and is responsible for homotypic protein-protein interactions:
- Interaction with ASC: The PYD recruits the adaptor protein ASC (PYCARD) through PYD-PYD interactions
- Oligomerization: AIM2 PYD mediates the formation of the inflammasome complex
- Signal integration: Serves as a platform for integrating upstream activation signals
¶ HIN-200 Domain
The C-terminal HIN-200 domain (approximately 200 amino acids) is the DNA-binding component:
- Oligosaccharide-binding (OB) folds: Two OB folds form a DNA-binding pocket
- dsDNA recognition: Binds double-stranded DNA of various lengths without sequence specificity
- Charge-dependent binding: DNA binding is mediated by electrostatic interactions with positively charged residues
The flexible linker between PYD and HIN-200 domains:
- Conformational flexibility: Allows the protein to adapt to different DNA binding scenarios
- Auto-inhibition: May contribute to keeping AIM2 in an inactive state in the absence of DNA
¶ DNA Sensing and Inflammasome Assembly
AIM2 functions as a pattern recognition receptor (PRR) for cytosolic double-stranded DNA:
- DNA binding: Cytosolic dsDNA binds to the HIN-200 domain of AIM2
- Conformational change: DNA binding induces oligomerization of AIM2
- Adaptor recruitment: The PYD recruits ASC adapter protein
- Caspase-1 activation: ASC recruits pro-caspase-1 to the complex
- Proteolytic cleavage: Active caspase-1 cleaves pro-IL-1β and pro-IL-18
- Cytokine release: Mature IL-1β and IL-18 are secreted
In the normal CNS, AIM2-mediated inflammasome activation serves protective functions:
- Defense against pathogens: Detects viral and bacterial DNA in infected cells
- Tumor surveillance: Recognizes DNA from abnormal cells
- DNA damage response: May sense genomic instability
- Cell death regulation: Controls pyroptotic cell death pathways
AIM2 is expressed throughout the body with particular relevance to immune cells:
- Microglia: High expression in brain-resident macrophages
- Neurons: Moderate expression, increases with cellular stress
- Astrocytes: Constitutive expression, upregulated in inflammation
- Peripheral immune cells: B cells, dendritic cells, macrophages
AIM2 plays a significant role in Alzheimer's disease pathogenesis through multiple mechanisms [4]:
Amyloid-β-Induced Inflammasome Activation:
- Aβ plaques contain DNA that can activate AIM2
- Aβ directly interacts with microglia to increase AIM2 expression
- AIM2 inflammasome activation contributes to chronic neuroinflammation
IL-1β-Mediated Pathology:
- Elevated IL-1β in AD brain correlates with disease severity
- IL-1β promotes tau phosphorylation and aggregation
- Sustained IL-1β release drives synaptic dysfunction
Neuroinflammation Amplification:
- AIM2 activation creates a feed-forward inflammatory loop
- Cytokine release attracts additional immune cells
- Contributes to the chronic inflammatory microenvironment
Therapeutic Implications:
- AIM2 inhibitors under development for AD
- Targeting inflammasome components may reduce neuroinflammation
AIM2 contributes to Parkinson's disease through several pathways [5]:
α-Synuclein-Induced Activation:
- α-Synuclein aggregates can trigger AIM2 inflammasome
- Microglial activation by α-synuclein increases AIM2 expression
- Inflammasome activation contributes to dopaminergic neuron loss
Neuroinflammation in PD:
- Post-mortem studies show increased AIM2 in PD substantia nigra
- IL-1β levels elevated in PD cerebrospinal fluid
- Inflammasome activation exacerbates motor symptoms
Mitochondrial DNA Sensing:
- Damaged mitochondria release mitochondrial DNA
- AIM2 may sense mitochondrial DNA in stressed neurons
- Contributes to inflammatory responses in PD
AIM2 has been implicated in multiple sclerosis (MS):
- Demyelination: Inflammasome activation in oligodendrocytes
- Blood-brain barrier: Disruption through inflammatory mediators
- Lesion formation: Contributes to chronic demyelinating lesions
In ALS, AIM2 contributes to motor neuron degeneration:
- Motor neuron vulnerability: High AIM2 expression in affected neurons
- Glial inflammation: Microglial AIM2 drives progressive inflammation
- Disease progression: Inflammasome activation correlates with progression
AIM2 inflammasome can be activated by:
- Viral DNA: Herpesviruses, adenoviruses, retroviruses
- Bacterial DNA: Intracellular bacterial pathogens
- Endogenous DNA: Genomic DNA, mitochondrial DNA
- DNA-containing aggregates: Amyloid, pathological proteins
- Genomic instability: DNA damage, micronuclei
dsDNA → AIM2 → ASC → Pro-caspase-1
↓
Active caspase-1
↓
┌───────────────────┴───────────────────┐
↓ ↓
Pro-IL-1β → IL-1β Pro-IL-18 → IL-18
↓ ↓
Pyroptosis Inflammation
Cell death Immune recruitment
AIM2 activity is tightly regulated:
- Post-translational modifications: Phosphorylation, ubiquitination
- Negative regulators: ASC antagonists, caspase inhibitors
- Cellular localization: Sequestration prevents inappropriate activation
- Epigenetic control: Transcriptional regulation of AIM2 expression
Several approaches target AIM2 inflammasome:
| Approach |
Mechanism |
Status |
Example |
| AIM2 inhibitors |
Block DNA binding |
Preclinical |
Small molecule inhibitors |
| ASC inhibitors |
Prevent inflammasome assembly |
Preclinical |
MCC950 |
| Caspase-1 inhibitors |
Block cytokine cleavage |
Clinical |
VX-765 |
| IL-1R antagonists |
Block cytokine signaling |
Approved |
Anakinra, Canakinumab |
Alzheimer's Disease:
- Ongoing trials with NLRP3 inflammasome inhibitors
- IL-1β targeting strategies in early trials
- Gene therapy approaches to reduce AIM2 expression
Parkinson's Disease:
- Inflammasome inhibitors in preclinical models
- IL-1β blockade shows neuroprotective effects
- Targeting microglial AIM2 activation
- Specificity: Ensuring AIM2 selectivity over other inflammasomes
- Delivery: Crossing the blood-brain barrier
- Timing: Optimal intervention point in disease course
- Safety: Balancing inflammation suppression with host defense
- AIM2 knockout mice: Reduced inflammation in disease models
- AIM2 overexpression: Increased susceptibility to inflammatory damage
- Humanized models: AIM2 expressed in human cells
- AD models: 5xFAD, APP/PS1 mice with AIM2 modulation
- PD models: MPTP, α-synuclein transgenic mice
- MS models: EAE (Experimental Autoimmune Encephalomyelitis)
Polymorphisms in the AIM2 gene have been associated with:
- Autoimmune diseases: SLE, rheumatoid arthritis
- Infectious disease susceptibility: Viral infections
- Cancer risk: Melanoma, other malignancies
- Neurological disease: Potential modifiers of AD/PD risk
AIM2-related biomarkers under investigation:
- IL-1β levels: Peripheral and CSF measurements
- ASC specks: Circulating inflammasome components
- AIM2 expression: Gene expression in immune cells
- Genetic markers: SNP associations with disease